Juvenile dermatomyositis: review and update of the pathogenesis and treatment.
Juvenile dermatomyositis (JDM) is an autoimmune disease characterized by systemic vasculopathy. Its main manifestations include symmetrical proximal muscle weakness, elevated serum muscle enzymes and cutaneous lesions, among which the heliotrope and Gottron's papules are pathognomonic. Early recognition and prompt therapy allow better prognosis and prevent the development of calcinosis. Although the treatment is based on glucocorticoids, the more commonly associated immunosuppressors include methotrexate, azathioprine, cyclosporine, and cyclophosphamide, depending on the severity of disease. The use of immunobiologicals for refractory cases remains under investigation, but the results are controversial or inexpressive. In this review, we highlight recent updates on the pathogenesis and treatment of JDM.
Medical School, Universidade de São Paulo (HCFMUSP), Brazil.
Nilton Salles
NS
Rosa Neto
Cláudia
C
Goldenstein-Schainberg
D003882:Dermatomyositis / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D006801:Humans